Live Breaking News & Updates on Hlaa 02

Stay updated with breaking news from Hlaa 02. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

OSE2101 Cancer Vaccine Yields Favorable OS vs SOC in HLA-A*02+ ICI-Resistant NSCLC

Benjamin Besse, MD, PhD, discusses the results from the ATALANTE-1 trial and details the mechanism of action of the OSE2101 vaccine. ....

France General , Benjamin Besse , Institute Gustave Roussy , Ose2101 , Cancer Vaccine , Atalante 1 Trial , Hlaa 02 ,